After taking a closer look at the potential impact of JZP-258, Jazz Pharmaceuticals' form of oxybate for narcolepsy, Piper Jaffray analyst David Amsellem reiterates an Overweight rating on the shares with a $213 price target. If JZP-258 were to capture a significant share of the oxybate market, that would translate into not only limited erosion of cash flows from Jazz's oxybate franchise, but also a "significant re-rating of valuation multiples" for Jazz, Amsellem tells investors in a research note. He believes a scenario involving greater than 50% market share for JZP-258 would translate into a value per share of north of $250. Further, the downside risk to the shares in a scenario with limited or no contribution from JZP-258 is "far more limited than the upside potential," contends Amsellem.